These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36561338)

  • 1. Altered states, alkaloids, and catatonia: Monoaminoxidase inhibitors and their role in the history of psychopharmacology.
    Buda O; Hostiuc S; Popa-Velea O; Boroghina S
    Front Pharmacol; 2022; 13():1053534. PubMed ID: 36561338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Multiple forms of monoaminoxidase in the rat brain during experimental catatonia].
    Kamyshanskaia NS; Gorkin VZ; Voĭtenko NN
    Vopr Med Khim; 1990; 36(5):32-4. PubMed ID: 2251787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insluin secretion.
    Feldman JM; Chapman B
    Diabetologia; 1975 Dec; 11(6):487-94. PubMed ID: 1107123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
    J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoamine Oxidase Inhibition by Plant-Derived β-Carbolines; Implications for the Psychopharmacology of Tobacco and Ayahuasca.
    Berlowitz I; Egger K; Cumming P
    Front Pharmacol; 2022; 13():886408. PubMed ID: 35600851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of monoamine oxidase in monoaminergic neurones in the rat brain by irreversible inhibitors.
    Fagervall I; Ross SB
    Biochem Pharmacol; 1986 Apr; 35(8):1381-7. PubMed ID: 2870717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-propargylbenzylamine, a major metabolite of pargyline, is a potent inhibitor of monoamine oxidase type B in rats in vivo: a comparison with deprenyl.
    Karoum F
    Br J Pharmacol; 1987 Feb; 90(2):335-45. PubMed ID: 3103805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors.
    Da Prada M; Kettler R; Keller HH; Burkard WP; Haefely WE
    J Neural Transm Suppl; 1989; 28():5-20. PubMed ID: 2677242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydride Abstraction as the Rate-Limiting Step of the Irreversible Inhibition of Monoamine Oxidase B by Rasagiline and Selegiline: A Computational Empirical Valence Bond Study.
    Tandarić T; Prah A; Stare J; Mavri J; Vianello R
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32858935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells.
    Nagatsu T; Sawada M
    J Neural Transm Suppl; 2006; (71):53-65. PubMed ID: 17447416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells.
    Inaba-Hasegawa K; Akao Y; Maruyama W; Naoi M
    J Neural Transm (Vienna); 2013 Mar; 120(3):435-44. PubMed ID: 22968599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic postnatal monoamine oxidase inhibition affects affiliative behavior in rat pupso.
    Blazevic S; Merkler M; Persic D; Hranilovic D
    Pharmacol Biochem Behav; 2017 Feb; 153():60-68. PubMed ID: 27989747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours.
    Finberg JP; Youdim MB
    Neuropharmacology; 2002 Dec; 43(7):1110-8. PubMed ID: 12504917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
    Youdim MB; Weinstock M
    Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Modification of mitochondrial monoamine oxidase activity by certain amine inhibitors].
    Baumanis EA; Kalninia IE; Iriste AA; Gorkin VZ
    Vopr Med Khim; 1981; 27(1):72-7. PubMed ID: 6781140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoamine oxidase inhibitors: a new generation.
    Robinson DS
    Psychopharmacol Bull; 2002; 36(3):124-38. PubMed ID: 12473970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoamine oxidase A inhibitor occupancy during treatment of major depressive episodes with moclobemide or St. John's wort: an [11C]-harmine PET study.
    Sacher J; Houle S; Parkes J; Rusjan P; Sagrati S; Wilson AA; Meyer JH
    J Psychiatry Neurosci; 2011 Nov; 36(6):375-82. PubMed ID: 21463543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of monoamine oxidase inhibitors.
    Mallinger AG; Smith E
    Psychopharmacol Bull; 1991; 27(4):493-502. PubMed ID: 1813896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human monoamine oxidase enzyme inhibition by coffee and beta-carbolines norharman and harman isolated from coffee.
    Herraiz T; Chaparro C
    Life Sci; 2006 Jan; 78(8):795-802. PubMed ID: 16139309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MAO-inhibitors in Parkinson's Disease.
    Riederer P; Laux G
    Exp Neurobiol; 2011 Mar; 20(1):1-17. PubMed ID: 22110357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.